Odds of mortality or discharge to hospice reduced for those receiving supplemental oxygen or mechanical ventilation and/or ECMO
Early Steroid Use Does Not Cut Hospital Stay for Non-MIS-C COVID-19
Early use of steroids in children hospitalized for COVID-19 without MIS-C not associated with shorter length of stay
COVID-19 Incidence Not Increased With Corticosteroid Injections
Incidence of COVID-19 lower for adults receiving image-guided corticosteroid injections for pain management
Inflammation During COVID-19 Hospitalization Linked to Mortality
Elevated C-reactive protein during hospitalization associated with increased mortality risk after recovery from COVID-19
Continued Dexamethasone at Discharge Not Tied to Better COVID-19 Outcomes
No association seen with reduced 14-day all-cause readmission or mortality for individuals continuing dexamethasone at discharge
Higher Dose of Steroid Does Not Improve Outcomes in Severe COVID-19
Number of days alive without life support at day 28 did not differ with dexamethasone 12 mg versus 6 mg in those with severe hypoxemia
Intranasal Corticosteroids Tied to Less Severe COVID-19 Outcomes
Findings seen among individuals regularly using steroid nasal sprays before COVID-19 diagnosis
Dexamethasone Underused for Adults Hospitalized With COVID-19
Dexamethasone and remdesivir use have gradually increased during the pandemic; hydroxychloroquine use peaked in March 2020
Immunomodulation With IVIG, Glucocorticoids Examined in MIS-C
Early outcomes of two large observational studies show mixed results for the efficacy of immunomodulation with IVIG, glucocorticoids, or both
Drug-Induced Immunosuppression Examined in U.S. Adults
Drug-induced immunosuppression, particularly from oral corticosteroids, may limit response to COVID-19 vaccine
- Page 1 of 2
- 1
- 2